Article in Acta crystallographica. Section F, Structural biology communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors.
Alex MendezChemistry and Biochemistry Department, Hampton University, 200 William R. Harvey Way, Hampton, VA 23668, USA.
Cydni BollingChemistry and Biochemistry Department, Hampton University, 200 William R. Harvey Way, Hampton, VA 23668, USA.ORCID 0009-0004-9996-5693
Shane TaylorChemistry and Biochemistry Department, Hampton University, 200 William R. Harvey Way, Hampton, VA 23668, USA.
Stanley MakumireStructural Biology Research Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, Aapistie 7C, 90220 Oulu, Finland.ORCID 0000-0003-4355-1382
Bart StakerCenter for Global Infectious Disease Research, Seattle Children's Research Institute, 307 Westlake Avenue North, Suite 500, Seattle, WA 98109, USA.
Alexandra ReersSeattle Structural Genomics Center for Infectious Diseases, Seattle, Washington, USA.
Brad HammersonSeattle Structural Genomics Center for Infectious Diseases, Seattle, Washington, USA.
Stephen J MayclinSeattle Structural Genomics Center for Infectious Diseases, Seattle, Washington, USA.ORCID 0000-0002-1600-4554
Jan AbendrothSeattle Structural Genomics Center for Infectious Diseases, Seattle, Washington, USA.ORCID 0000-0002-8229-3243
Donald D LorimerSeattle Structural Genomics Center for Infectious Diseases, Seattle, Washington, USA.ORCID 0000-0002-9638-8083
Thomas E EdwardsSeattle Structural Genomics Center for Infectious Diseases, Seattle, Washington, USA.ORCID 0000-0002-0474-8003
Edward W TateImperial College London, South Kensington Campus, London SW7 2AZ, United Kingdom.
Sandhya SubramanianCenter for Global Infectious Disease Research, Seattle Children's Research Institute, 307 Westlake Avenue North, Suite 500, Seattle, WA 98109, USA.
Andrew S BellMyricx Pharma, 125 Wood Street, London EC2V 7AN, United Kingdom.ORCID 0000-0002-0581-9387
Peter J MylerCenter for Global Infectious Disease Research, Seattle Children's Research Institute, 307 Westlake Avenue North, Suite 500, Seattle, WA 98109, USA.ORCID 0000-0002-0056-0513
Oluwatoyin A AsojoDartmouth Cancer Center, One Medical Center Drive, Lebanon, NH 03756, USA.ORCID 0000-0002-4043-2700
Graham ChakafanaChemistry and Biochemistry Department, Hampton University, 200 William R. Harvey Way, Hampton, VA 23668, USA.ORCID 0000-0003-4539-3971
Funding
Centers for Research on Structural Biology of Infectious Diseases: Universal Influenza Vaccine Research75N93022C00036 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI STAKER, BART · 2022 to 2025
$21.7M
Structural Analysis and Inhibitor Optimization of Cryptosporidium n-myristoyltransferase for Drug DiscoveryR01AI155536 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI STAKER, BART LEE · 2021 to 2025
$4.2M
U-RISE at Hampton UniversityT34GM136489 · NIGMS · HAMPTON UNIVERSITY · PI EREBHOLO, FRANCIS, NJOKI, PETER · 2020 to 2024
$1.5M
HU-CHEM: Deploying evidence-based interventions in Chemistry at Hampton University to plug leaks in the biomedical training pipelineU01GM138433 · NIGMS · HAMPTON UNIVERSITY · PI ASOJO, OLUWATOYIN AJIBOLA · 2020 to 2022
Plasmodium vivax, a significant contributor to global malaria cases, poses an escalating health burden on a substantial portion of the world's population. The increasing spread of P. vivax because of climate change underscores the development of new and rational drug-discovery approaches. The Seattle Structural Genomics Center for Infectious Diseases is taking a structure-based approach by investigating essential enzymes such as N-myristoyltransferase (NMT). P. vivax N-myristoyltransferase (PvNMT) is a promising target for the development of novel malaria treatments unlike current drugs, which target only the erythrocytic stages of the parasite. Here, the 1.8 Å resolution ternary structure of PvNMT in complex with myristoyl-CoA and IMP-1088, a validated NMT inhibitor, is reported. IMP-1088 is a validated nonpeptidic inhibitor and a ternary complex structure with human NMT has previously been reported. IMP-1088 binds similarly to PvNMT as to human NMT.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.